With Additional Active Ingredient Patents (Class 514/171)
-
Patent number: 10323003Abstract: The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases.Type: GrantFiled: November 3, 2017Date of Patent: June 18, 2019Assignee: CHIESI FARMACEUTICI S.p.A.Inventors: Alessandro Falchi, Emilio Lutero, Emanuele Ferrari, Fausto Pivetti, Rocco Bussolati, Edoardo Mariani, Orsola Vecchi, Erhard Bappert, Caterina Ventrici
-
Patent number: 10300077Abstract: The present disclosure is directed to methods, compositions, and kits for treating dementia.Type: GrantFiled: September 8, 2017Date of Patent: May 28, 2019Inventor: Steven Hoffman
-
Patent number: 10265329Abstract: A method of treating steroid-dependent disease such as prostate cancer in a subject is described that includes administering a therapeutically effective amount a CYP17A inhibitor and an effective amount of a 5-?-reductase inhibitor to the subject.Type: GrantFiled: March 7, 2016Date of Patent: April 23, 2019Assignees: THE CLEVELAND CLINIC FOUNDATION, THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Nima Sharifi, Zhenfei Li, Richard Auchus
-
Patent number: 10258058Abstract: A method for preparing functional edible oil rich in phytosterol esters and diglycerides includes steps of: 1) adding a raw material: adding phytosterol, triglyceride and a molecular sieve into a reactor, wherein a ratio of the phytosterol and the triglyceride is 1:2-1:4, a molecular sieve amount is 50 g/L; heating to 50-60° C. and stirring for 30-60 min, for obtaining a pre-mixture; 2) providing non-aqueous enzymatic transesterification: adding 5-20 g/L lipase into the pre-mixture, adding 100-200 ppm antioxidant, stirring and reacting for 8-12 h with a temperature of 50-60° C. and an atmospheric pressure, stopping heating and naturally cooling to a room temperature; and 3) post-treating: after reaction, removing the lipase and the molecular sieve by centrifugation, for obtaining the functional edible oil. The functional edible oil rich in two nutritional active components is obtained by the one-step method. Products of the present invention do not need separation and purification, and operation is simple.Type: GrantFiled: May 7, 2017Date of Patent: April 16, 2019Assignee: OIL CROPS RESEARCH INSTITUTE, CHINESE ACADEMY OF AGRICULTURAL SECIENCESInventors: Fenghong Huang, Mingming Zheng, Shi Wang, Xia Xiang, Jie Shi, Qianchun Deng, Wenlin Li, Chuyun Wan
-
Patent number: 10251880Abstract: Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.Type: GrantFiled: November 26, 2014Date of Patent: April 9, 2019Assignee: SATIOGEN PHARMACEUTICALS, INC.Inventors: Bronislava Gedulin, Andrew A. Young, Howard E. Greene
-
Patent number: 10245272Abstract: A transmembrane penetration enhancer includes a thermotropic liquid crystal suitably prepared for use in a therapeutic system to improve delivery of at least one active ingredient across a biomembrane and/or skin. The thermotropic liquid crystal comprises at least one cholesteryl ester and is effective in a mesomorphic state at a temperature of the biomembrane and/or skin. A therapeutic system includes the prepared thermotropic liquid crystal for enhanced transmembrane penetration and at least one active ingredient for delivery by the thermotropic liquid crystal. A method for making and using the transmembrane penetration enhancer is presented.Type: GrantFiled: October 25, 2010Date of Patent: April 2, 2019Inventors: Iryna Kravchenko, Sergiy Lozovsky
-
Patent number: 10238637Abstract: Modulators of adenosin A3 receptors of formula (I): And procedure for preparing these compounds. Other objectives of the present invention are to provide pharmaceutical compositions comprising an effective amount of these compounds and the use of the compounds for manufacturing a medicament for the treatment of pathological conditions or diseases that can improve by modulation of the adenosine A3 receptor.Type: GrantFiled: January 22, 2016Date of Patent: March 26, 2019Assignee: PALOBIOFARMA, S.L.Inventors: Julio Castro-Palomino Lária, Juan Camacho Gómez
-
Patent number: 10195408Abstract: Certain embodiments of the invention relates to a transdermal drug delivery system containing donepezil or a pharmaceutically acceptable salt thereof as an active ingredient, more specifically to a transdermal drug delivery system containing a drug-containing matrix layer comprising donepezil or its pharmaceutically acceptable salt, a styrene copolymer, a hydrogenated rosin glycerol ester, and optionally a hydrocarbon resin.Type: GrantFiled: February 20, 2015Date of Patent: February 5, 2019Assignee: NAL PHARMACEUTICAL GROUP LIMITEDInventors: Y. Joseph Mo, Tiffany Kawai
-
Patent number: 10155005Abstract: The present disclosure is directed to generally methods for treating mammographic breast density and/or breast stiffness in a patient in need thereof, such as a premenopausal or perimenopausal patient, comprising the administration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor. These methods may also be useful in post-menopausal woman.Type: GrantFiled: March 16, 2017Date of Patent: December 18, 2018Assignee: HAVAH THERAPEUTICS PTY LTD.Inventor: Stephen Nigel Birrell
-
Patent number: 10150774Abstract: The subject matter generally relates to compounds and methods of treatment and/or prophylaxis of CNS diseases, disorders, and/or injuries. In one aspect, the subject matter relates to inhibitors of phosphodiesterase 1 (PDE1) as neuroprotective agents and/or neural regenerative agents. In a further aspect, the subject matter relates to individuals that are at risk for the development of CNS disease or disorder.Type: GrantFiled: September 17, 2015Date of Patent: December 11, 2018Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Peng Li, Hailin Zheng, Jun Zhao, Lawrence Wennogle
-
Patent number: 10112918Abstract: The invention relates to a derivative of 15-oxospiramilacton, particularly to a compound of Formula I or II, or an isomer, a solvate or a pharmaceutically acceptable salt thereof. The invention also relates to a pharmaceutical composition comprising the compound as pharmaceutically active ingredient, a method for preparing the same, and use thereof in manufacture of an anti-tumor agent. The derivative of 15-oxospiramilactone of the invention have an activity against multiple tumor cell lines, and the anti-tumor activity is positively correlated to an activity inhibiting the Wnt signaling pathway.Type: GrantFiled: April 21, 2014Date of Patent: October 30, 2018Assignees: Kunming Institute of Botany, The Chinese Academy of Sciences, The Key Laboratory of Chemistry for Natural Product of Guizhou Province and Chinese Academy of Science, Shanghai Institutes of Biological Sciences, CAS, Institute of Zoology, Chinese Academy of SciencesInventors: Xiaojiang Hao, Chen Yan, Haiyang Liu, Lin Li, Xiaoli He, Quan Chen
-
Patent number: 10092523Abstract: The present invention relates to long acting pharmaceutical compositions or pharmaceutically acceptable salts thereof, useful in the treatment or prevention of Human Immunodeficiency Virus (HIV) infections.Type: GrantFiled: September 24, 2015Date of Patent: October 9, 2018Assignee: GlaxoSmithKline Intellectual Property (No. 2) LimitedInventor: Brian Alvin Johns
-
Pharmaceutical composition containing a compound having a thrombopoietin receptor agonistic activity
Patent number: 10085973Abstract: The present inventor has found out that the following criteria enable to ensure an effect for increasing the platelet count while preventing an excessive increase in the platelet count; “when the platelet count has increased by a certain amount and reached to a sufficient level of the platelet count during administration of a pharmaceutical composition containing a compound having a thrombopoietin receptor agonistic activity, administration of the pharmaceutical composition is discontinued thereafter”.Type: GrantFiled: July 14, 2016Date of Patent: October 2, 2018Assignee: Shionogi & Co., Ltd.Inventors: Takeshi Kano, Takahiro Fukuhara, Takayuki Katsube -
Patent number: 10080732Abstract: A method of stimulating ventilatory and/or respiratory drive in a subject in need thereof includes administering to the subject a therapeutically effective amount of a composition comprising a cystine ester or a pharmaceutically acceptable salt thereof. Embodiments described herein relate to compositions and methods of stimulating ventilatory and/or respiratory drive in a subject in need thereof, and particularly relates to compositions and methods of treating breathing diseases and/or disorders associated with impaired ventilatory and/or respiratory drive.Type: GrantFiled: January 13, 2016Date of Patent: September 25, 2018Assignee: Case Western Reserve UniversityInventors: Benjamin Gaston, Stephen Lewis
-
Patent number: 10076505Abstract: The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The invention also relates to kits for treatment and/or prevention of ischemic lesions, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: July 24, 2017Date of Patent: September 18, 2018Assignee: United Therapeutics CorporationInventor: Michael Wade
-
Patent number: 10071130Abstract: Embodiments of the invention are directed to methods of treating cancer cells, particularly breast cancer cells, such as chemo-resistant cells, with an Hsp90 inhibitor and an anticancer agent or compound such as chemotherapy.Type: GrantFiled: December 12, 2014Date of Patent: September 11, 2018Assignee: The University of ChicagoInventor: Suzanne D. Conzen
-
Patent number: 10049866Abstract: A method for analyzing an aliphatic compound by mass spectrometry which comprises: (i) ionizing an aliphatic compound in the presence of a heterocyclic modifier; and (ii) mass analyzing the resulting ions to obtain mass spectrometric data.Type: GrantFiled: April 14, 2017Date of Patent: August 14, 2018Assignee: MICROMASS UK LIMITEDInventors: David Douce, Gareth R. Jones
-
Patent number: 10034848Abstract: Disclosed herein is a method for increasing the dendritic spine formation or dendritic spine density in a subject, who is affected by a dendritic spine defect caused by the impairment in neurofibromin (NF1 protein), valosin-containing protein (VCP), atlastin-1 (ATL1), or superoxide dismutase 1 (SOD1). Accordingly, also disclosed herein is a method for treating a subject having or suspected of having a synaptopathy caused by the impairment in NF1, VCP, ATL1, or SOD1.Type: GrantFiled: October 28, 2015Date of Patent: July 31, 2018Assignee: Academia SinicaInventor: Yi-Ping Hsueh
-
Patent number: 10017506Abstract: Disclosed are bicyclic aryl compounds of formula (I), that can modulate the activity of the autotaxin (ATX) enzyme. This invention further relates to compounds that are ATX inhibitors, and methods of making and using such compounds in the treatment of demyelination due to injury or disease, as well as for treating proliferative disorders such as cancer.Type: GrantFiled: October 18, 2016Date of Patent: July 10, 2018Assignee: BIOGEN MA INC.Inventors: Kevin M. Guckian, Gnanasambandam Kumaravel, Bin Ma, Sha Mi, Hairuo Peng, Zhaohui Shao, Lihong Sun, Arthur G. Taveras, Deping Wang, Zhili Xin, Lei Zhang
-
Patent number: 9995755Abstract: Methods of diagnosing and treating disorders related to TH2 inhibition, including but not limited to asthma, are provided. Also provided are methods of selecting or identifying patients for treatment with certain therapeutic agents that are TH2 pathway inhibitors.Type: GrantFiled: September 9, 2013Date of Patent: June 12, 2018Assignee: GENENTECH, INC.Inventors: Joseph R. Arron, Richard W. Erickson, Michelle Freemer, Meredith Hazen, Guiquan Jia, John G. Matthews, Wendy Putnam, Heleen Scheerens, Yanan Zheng
-
Patent number: 9977033Abstract: Certain embodiments are directed to methods of identifying a subject having a higher risk of prostate cancer recurrence. The methods can include the step of measuring levels of one or more of FLIP, transcription factor Sp1, and transcription factor Sp3 in a prostate sample from the subject, wherein elevated levels of FLIP, transcription factor Sp1, and transcription factor Sp3 identify a subject as high risk for prostate cancer recurrence.Type: GrantFiled: September 11, 2013Date of Patent: May 22, 2018Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Addanki Pratap Kumar, Izhar Singh Batth, Rita Ghosh, Roble Bedolla, Ian M. Thompson, Jr.
-
Patent number: 9970935Abstract: Methods are provided herein for the use of Gli-1 as a specific marker for myofibroblast progenitor cells, thereby permitting the diagnosis of early stages of fibrosis prior to the onset of organ failure. Also provided herein are methods of isolating Gli-1+ cells for e.g., use in high-throughput screening of compounds for the treatment or prevention of fibrosis. In another aspect, provided herein are methods of treating or preventing fibrosis (e.g., kidney fibrosis) in a subject by administering a Gli inhibitor, particularly a Gli-2 inhibitor or a Gli-1/Gli-2 inhibitor.Type: GrantFiled: February 6, 2015Date of Patent: May 15, 2018Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Benjamin D. Humphreys, Rafael Kramann, Derek Dirocco
-
Patent number: 9970059Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.Type: GrantFiled: November 13, 2014Date of Patent: May 15, 2018Assignees: The United States of America, as represented by the Secretary, Department of Human Services, Arizona Board of Regents on behalf of the University of Arizona, Queen Mary University of London, Board of Regents of the University of Nebraska, Oslo University Hospital HF, Oregon Health & Science University, University of Rochester, Hospital Clinic de Barcelona, Universitat de Barcelona, British Columbia Cancer Agency Branch, Julius-Maximilians-University of WürzburgInventors: Lisa Rimsza, Andrew T. Lister, Wing C. Chan, Dennis Weisenburger, Jan Delabie, Erlend B. Smeland, Harald Holte, Stein Kvaloy, Rita M. Braziel, Richard I. Fisher, Pedro Jares, Armando Lopez-Guillermo, Elias Campo Guerri, Elaine S. Jaffe, Georg Lenz, Wyndham H. Wilson, George Wright, Sandeep S. Dave, Louis M. Staudt, Randy D. Gascoyne, Joseph M. Connors, Hans-Konrad Muller-Hermelink, Andreas Rosenwald, German Ott
-
Patent number: 9962360Abstract: The invention relates to compositions and methods useful for enhancing hair growth and promoting skin regeneration. Particularly, the invention provides topical compositions including trimebutine, salts, or active metabolites thereof, for enhancing or inducing hair growth and promoting skin regeneration. Compositions comprising trimebutine or a pharmaceutically acceptable salt or active metabolite thereof and their use in the method of promoting hair growth or skin regeneration. Preferably trimebutine is trimebutine maleate or N-desmethyl trimebutine. Compositions are preferably in a form for topical administration, such as a gel.Type: GrantFiled: September 25, 2015Date of Patent: May 8, 2018Assignee: The Hospital for Sick ChildrenInventors: Freda D. Miller, David R. Kaplan, Sibel Naska, Kristen Michelle Smith, Maryline Paris
-
Patent number: 9962384Abstract: Disclosed is a levosimendan compound, an optically active isomer thereof, or a pharmaceutically acceptable salt thereof, which is used for the prevention and/or treatment of diseases caused by tau aggregation or phosphorylation, such as neurodegenerative diseases (e.g., Alzheimer disease). In accordance with yet another aspect of the present invention, there is provided a health functional food for preventing or treating tau aggregation-related diseases, containing a levosimendan compound or a pharmaceutically acceptable salt, stereoisomer or solvate thereof.Type: GrantFiled: September 7, 2017Date of Patent: May 8, 2018Assignee: Korea Institute of Science and TechnologyInventors: Yun Kyung Kim, Sung Su Lim, Do Hee Kim, Md. Mamunul Haque, Seul Gi Shin, Ha Eun Lee, Tae Hun Kim, Sang Min Lim, Ae Nim Pae
-
Patent number: 9962369Abstract: One aspect of the invention relates to AI-helper compositions comprising an AI compound (e.g., melatonin, alpha-lipoic acid, vitamin E, vitamin D, glutathione, resveratrol, astaxanthin, beta carotene, vitamin A, vitamin C, vitamin B12, vitamin B6, folic acid, and taurine) and one or more helper esters. The AI-helper compositions disclosed herein can be used for effective transdermal delivery of the AI compound to a subject. Another aspect of the invention relates to applications and preparations of the AI-helper compositions.Type: GrantFiled: March 10, 2015Date of Patent: May 8, 2018Assignee: SPRAYABLE HOLDINGS, INC.Inventor: Benjamin M. Yu
-
Patent number: 9925168Abstract: Crystalline micronized particulate of a glycopyrronium salt may be prepared by hydrodynamic cavitation. The resulting drug particles are physically stable with regard to agglomeration and/or aggregation on storage.Type: GrantFiled: January 19, 2017Date of Patent: March 27, 2018Assignee: CHIESI FARMACEUTICI S.p.A.Inventors: Stephen P. Davanzo, Barry E. Nall, Timothy J. Rouse, Michele Miozzi
-
Patent number: 9925216Abstract: The mixture of un-refined salt and sugar in the manufacture of a medicament employed for treating lax vagina syndrome or colpoxerosis disease in a mammal. Various tests, vaginal smooth muscle contractility test using New Zealand White Rabbit; (Experimental example 1); the effect on the vagina contractility in volunteers by using perinometer (Experimental example 2); and the effect on the colpoxerosis disease in volunteers (Experimental example 3), showed improving effect on the contractility of vagina tissue and colpoxerosis disease. Accordingly, the combination can be useful in treating or preventing lax vagina syndrome or colpoxerosis disease.Type: GrantFiled: August 29, 2017Date of Patent: March 27, 2018Inventor: Won Seog Choi
-
Patent number: 9925183Abstract: The embodiments described herein include methods and formulations for treating viruses and diseases that are exacerbated by inflammatory responses in the body. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient.Type: GrantFiled: March 6, 2017Date of Patent: March 27, 2018Assignee: Inflammatory Response Research, Inc.Inventor: Bruce Chandler May
-
Patent number: 9907785Abstract: Provided is a composition for use in treating a skin condition, the composition comprising: (a) a first component comprising a substituted or unsubstituted diindolylmethane compound; and (b) a second component comprising a substituted or unsubstituted retinoid compound.Type: GrantFiled: April 25, 2016Date of Patent: March 6, 2018Assignee: SKINTECH LIFE SCIENCE LIMITEDInventor: David Alpert
-
Patent number: 9867850Abstract: The mixture of processed salt and sugar in the manufacture of a medicament employed for treating lax vagina syndrome or colpoxerosis disease in a mammal. Various tests, vaginal smooth muscle contractility test using New Zealand White Rabbit; (Experimental example 1); the effect on the vagina contractility in volunteers by using perinometer (Experimental example 2); and the effect on the colpoxerosis disease in volunteers (Experimental example 3), showed improving effect on the contractility of vagina tissue and colpoxerosis disease. Accordingly, the combination can be useful in treating or preventing lax vagina syndrome or colpoxerosis disease.Type: GrantFiled: August 29, 2017Date of Patent: January 16, 2018Inventor: Won Seog Choi
-
Patent number: 9855245Abstract: The present disclosure is directed to methods for reducing cardiovascular risk in a human subject by administering atrasentan, or a pharmaceutically acceptable salt thereof, in an amount sufficient to effect a reduction of about 5% or more in one or both of (a) total serum cholesterol, relative to the subject's baseline total serum cholesterol, and (b) serum LDL cholesterol, relative to the subject's baseline serum LDL cholesterol.Type: GrantFiled: April 30, 2014Date of Patent: January 2, 2018Assignee: AbbVie Inc.Inventors: Blas Coll Crespo, Dennis Andress, John J. Brennan, James C. Stolzenbach
-
Patent number: 9795653Abstract: A use of an inhalable powder formulation for preventing or treating an NMDA receptor hypofunction-related disease, a method for preventing or treating an NMDA receptor hypofunction-related disease in a subject, which comprises administering a therapeutically effective amount of an inhalable powder formulation comprising growth hormone (GH) to the subject in need thereof, and an inhalable powder formulation for preventing or treating an NMDA receptor hypofunction-related disease comprising GH as an active ingredient are provided.Type: GrantFiled: February 14, 2014Date of Patent: October 24, 2017Assignee: MediGeneBio CorporationInventors: Sy Lee, Sung-Ick Park
-
Patent number: 9771339Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit cystathionine-?-lyase (CSE). Also described herein are methods for using such CSE inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from CSE inhibition.Type: GrantFiled: July 23, 2013Date of Patent: September 26, 2017Assignee: SOVA PHARMACEUTICALS, INC.Inventors: Sergio G. Durón, Justin Chapman, Simon G. Sydserff, Srinivas G. Rao, Gregory Stein
-
Patent number: 9766224Abstract: A method of analyzing a population of cells is disclosed. In certain embodiments, the method includes i) obtaining an array of cells on a substrate, wherein the cells are labeled with one or more mass tags and are separated from one another, ii) measuring, using secondary ion mass spectrometry (SIMS), the abundance of the one or more mass tags at a plurality of locations occupied by the cells, thereby generating, for each individual cell measured, a set of data, and iii) outputting the set of data for each of the cells analyzed. Also provided herein are systems that find use in performing the subject method. In some embodiments, the system is an automated system for analyzing a population of cells using SIMS.Type: GrantFiled: March 11, 2016Date of Patent: September 19, 2017Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Garry P. Nolan, Sean C. Bendall, Robert M. Angelo
-
Patent number: 9757388Abstract: The present invention relates to lower dosage strength pernasal testosterone gel formulations for intranasal administration and treatment methods for using the lower dosage strength pernasal testosterone gel formulations for treating a female subject with anorgasmia and/or hypoactive sexual desire disorder.Type: GrantFiled: May 14, 2012Date of Patent: September 12, 2017Assignee: Acerus Pharmaceuticals SRLInventors: Wayne Kreppner, Siobhan Fogarty, Werner Oberegger, Paul Maes
-
Patent number: 9737508Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: GrantFiled: September 20, 2016Date of Patent: August 22, 2017Assignee: MENLO THERAPEUTICS INC.Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
-
Patent number: 9737518Abstract: The present invention relates to respirable dry powder comprising respirable dry particles that comprise sodium chloride, leucine, and tiotropium bromide, wherein the sodium chloride is about 60% to about 90%, the leucine is about 10% to about 40%, the tiotropium bromide is about 0.01% to about 0.5%, and optionally one or more additional therapeutic agents up to about 20%, wherein all percentages are weight percentages on a dry basis and all the components of the respirable dry particles amount to 100%. The invention also relates to respirable dry powders that contain respirable dry particles that comprise sodium chloride, leucine, and tiotropium bromide, wherein the sodium chloride is 67% to 84%, the leucine is 12% to 28%, the tiotropium bromide is about 0.01% to about 0.5%, and optionally one or more additional therapeutic agents up to about 20%, wherein all percentages are weight percentages on a dry basis and all the components of the respirable dry particles amount to 100%.Type: GrantFiled: September 30, 2015Date of Patent: August 22, 2017Assignee: Pulmatrix Operating Company, Inc.Inventors: Jean C. Sung, Diana Manzanedo, Jason M. Perry, Wesley Dehaan, Brian Trautman
-
Patent number: 9737507Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: GrantFiled: September 19, 2016Date of Patent: August 22, 2017Assignee: MENLO THERAPEUTICS INC.Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
-
Patent number: 9730889Abstract: Provided herein is a pharmaceutical composition combination which comprises (a) a corticosteroid and (b) b-adrenergic receptor antagonist characterised in that active ingredients (a) and (b) form part of a single composition. Further provided is a method of treating a human or animal patient suffering from or susceptible to a respiratory disease or condition, said method comprises simultaneously, concurrently, separately or sequentially administering to the patient an effective amount of a b-adrenergic receptor antagonist and a corticosteroid.Type: GrantFiled: May 8, 2012Date of Patent: August 15, 2017Assignee: University of Houston SystemInventors: Richard A. Bond, Burton F. Dickey, Michael J. Tuvim
-
Patent number: 9717739Abstract: The invention relates to 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives of Formula I with progesterone antagonizing action and method of production thereof, use thereof for the treatment and/or prophylaxis of diseases and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular of fibroids of the uterus (myomas, uterine leiomyoma), endometriosis, heavy menstrual bleeds, meningiomas, hormone-dependent breast cancers and complaints associated with the menopause or for fertility control and emergency contraception.Type: GrantFiled: June 4, 2015Date of Patent: August 1, 2017Assignee: BAYER INTELLECTUAL PROPERTY GMBHInventors: Wolfgang Schwede, Ulrich Klar, Carsten Moller, Andrea Rotgeri, Wilhelm Bone
-
Patent number: 9718772Abstract: Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2?-methyl-1,1-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime is disclosed. A pharmaceutical composition containing the crystalline compound and methods for treating conditions related to the OT-R activity, such as preterm labor, and tor increasing embryo implantation rate in a mammal undergoing embryo transfer, comprising administering the crystalline compound are also disclosed.Type: GrantFiled: June 10, 2015Date of Patent: August 1, 2017Assignee: ObsEva S.A.Inventor: André Chollet
-
Patent number: 9713599Abstract: The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The invention also relates to kits for treatment and/or prevention of ischemic lesions, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: February 24, 2015Date of Patent: July 25, 2017Assignee: United Therapeutics CorporationInventor: Michael Wade
-
Patent number: 9707209Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: GrantFiled: September 20, 2016Date of Patent: July 18, 2017Assignee: MENLO THERAPEUTICS INC.Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
-
Patent number: 9707208Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: GrantFiled: September 19, 2016Date of Patent: July 18, 2017Assignee: MENLO THERAPEUTICS INC.Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
-
Patent number: 9707192Abstract: Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments of the composition are administered, for example, by injection, and/or transdermally.Type: GrantFiled: July 10, 2014Date of Patent: July 18, 2017Assignee: NEOTHETICS, INC.Inventor: John Daniel Dobak
-
Patent number: 9700567Abstract: Effective treatments of acute pain for extended periods of time are provided. Through the administration of an effective amount of dexamethasone at or near a target site, one can relieve pain cause by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least twenty-five days. In some embodiments, the relief can be for at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.Type: GrantFiled: October 30, 2014Date of Patent: July 11, 2017Assignee: Warsaw Orthopedic, Inc.Inventors: John M. Zanella, Vanja M. King, Christopher M. Hobot, Stephen M. Cox, William F. McKay, Kathy L. Remsen
-
Patent number: 9687455Abstract: Contained herein are compositions, formulations, methods, and kits for treating regional fat deposits and fat-related conditions. Certain methods comprise administering tetradecyl sulfate, tetradecyl sulfate-like compounds, and pharmaceutically or cosmetically acceptable salts, solvates, prodrugs, or esters thereof and a liquid carrier.Type: GrantFiled: August 14, 2015Date of Patent: June 27, 2017Inventor: John Daniel Dobak
-
Patent number: 9687423Abstract: Provided is a method for preparing a nanoemulsion, including mixing an oil phase part (A) containing a ceramide or derivative thereof, cholesterol, non-ionic surfactant, phospholipid and a polyol, a perfume part (B) containing a perfume ingredient, non-ionic surfactant and an alcohol, and an aqueous phase part (C) containing the other water-soluble active ingredients. When a nanoemulsion is obtained by the method, it is possible to reduce processing time and cost since a non-ionic surfactant is used without a high-pressure emulsification process, and the obtained nanoemulsion is more stable against a change in temperature than the other solubilized formulations.Type: GrantFiled: August 12, 2014Date of Patent: June 27, 2017Assignee: COSMAX, INC.Inventors: Jun Bae Lee, Chun Ho Park, Moung Seok Yoon, Hee Chang Ryoo
-
Patent number: 9655868Abstract: Disclosed herein are naphthoquinone analogs, such as plumbagin, pharmaceutical compositions that include naphthoquinone analogs, such as plumbagin, and methods of treating diseases and/or conditions such as cancer with naphthoquinone analogs, such as plumbagin. Also included are combination therapies wherein a naphthoquinone analog, such as plumbagin, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.Type: GrantFiled: August 18, 2015Date of Patent: May 23, 2017Assignee: Pellficure Pharmaceuticals, Inc.Inventor: Per Borgström